hsv2 dna vaccine

Vaccineexperimental

Clinical trial activity

2 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2004 (NCT00274300)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • HSV-2Immunity, active

    HSV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • hsv2 dna vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04222985Phase 1/Phase 2 (Phase 2)Jan 30, 2020Immune Design, Sanofi-Aventis
NCT00274300Phase 1Aug 1, 2004PowderMed, The University of Texas, Dallas
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Immune DesignFor profit1012020
PowderMedFor profit1112004
Sanofi-AventisFor profit1112020
The University of Texas, DallasAcademic/Hospital1012004
4 organizations
Page 1 / 1